

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
H. UEMURA et al.)	Examiner:
Appln. No.: 09/856,320)	Washington, D.C.
Filed: May 21, 2001)	October 22, 2001
For: NOVEL SERINE PROTEASE)	Atty. Docket: UEMURA=4
BSSP6)	

02 AUG 19 PM 3:36

RECEIVED
TECH CENTER 1600/2900

12/1
Prefault
8/22/02

**SUPPLEMENTAL PRELIMINARY AMENDMENT AND RESPONSE TO NOTICE TO
COMPLY WITH SEQUENCE LISTING REQUIREMENTS**

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply dated July 25, 2001, and prior to examination on the merits, petition and payment for a one month extension of time being attached hereto, please amend as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 28, line 9, with the following rewritten paragraph:

~~The vector is not specifically limited in so far~~
as it can express the protein of the present invention.
Examples thereof include pBAD/His, pRSETA, pCDNA2.1, pTrcHis2A, pYES2, pBlueBac4.5, pCDNA3.1 and pSecTag2 manufacture by Invitrogen, pET and pBAC manufactured by Novagen, pGEM manufactured by Promega, pBluescriptII manufactured by Stratagene, pGEX and pUC18/19 manufactured by Pharmacia, PfastBAC1 manufactured by GIBCO and the like.

02